Brentuximab Vedotin治疗复发或难治性Sézary综合征
这项回顾性病例系列纳入13例伴B2血液受累的Sézary综合征患者,接受每3周一次静脉brentuximab vedotin治疗,中位随访10.4个月。5例(38%)获全局缓解,含1例完全缓解;皮肤、血液、淋巴结缓解率分别为38%、63%、50%,周围神经病变4例、2例缓解。
要点
- 复发/难治性Sézary综合征中brentuximab vedotin全局缓解率38%,含1例完全缓解。
- 血液 compartment 缓解率最高(63%),皮肤CD30>10%与缓解无关。
- 周围神经病变4例,2例缓解;Grade 2不良事件包括神经病变、便秘和手足综合征。
核心结论
- 在复发或难治性Sézary综合征中,brentuximab vedotin对多个疾病 compartment 显示一定疗效,且用药方案可控、显著毒性发生率低。
研究设计与样本
- 2017年1月1日至2020年7月31日单中心回顾性病例系列,共13例18岁以上、诊断Sézary综合征且起始治疗时伴B2血液受累的患者。
- 中位随访10.4个月(范围1.4-34.6个月),干预为约每3周一次静脉brentuximab vedotin。
主要发现
- 13例中5例(38%)获全局缓解,中位6个周期,含1例完全缓解。
- 皮肤、血液、淋巴结缓解率分别为38%、63%、50%;11例瘙痒患者中3例(27%)改善。
- 9例检出皮肤CD30阳性(>10%),但与缓解无关;缓解者中位起效时间6周(范围6-9周),中位缓解持续时间5.5个月(范围2.5-28.9个月),中位至下一次治疗时间3.2个月(范围1.5-36.7个月)。
- 周围神经病变4例,其中2例缓解;Grade 2不良事件为神经病变2例、便秘1例、手足综合征1例。
关键数值与推荐
- 全局缓解按2011年EORTC-ISCL皮肤和淋巴结缓解标准及2018年ProCLIPI修订血液缓解标准评估。
临床怎么用
- 对复发或难治性Sézary综合征,brentuximab vedotin可考虑作为治疗选择之一,尤其需关注血液 compartment 缓解。
- 治疗期间应监测周围神经病变等不良事件,多数Grade 2事件可控。
局限性
- 回顾性单中心病例系列,样本量仅13例,证据级别有限。
- 中位随访10.4个月,随访时间较短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Treatment options for Sézary syndrome (SS) are limited and associated with low response rates. Brentuximab vedotin is a CD30-directed antibody-drug conjugate approved for refractory CD30-positive cutaneous T-cell lymphoma. However, limited data exist on its efficacy in SS, including in the pivotal phase 3 ALCANZA (A Phase 3 Trial of Brentuximab Vedotin (SGN-35) Versus Physician's Choice [Methotrexate or Bexarotene] in Participants With CD30-Positive Cutaneous T-Cell Lymphoma) trial. OBJECTIVE: To assess the preliminary efficacy and tolerability of brentuximab vedotin for SS. DESIGN, SETTING, AND PARTICIPANTS: From January 1, 2017, to July 31, 2020, a total of 13 patients with SS received brentuximab vedotin and were analyzed as part of a retrospective case series. Median follow-up was 10.4 months (range, 1.4-34.6 months). All patients were 18 years or older with a diagnosis of SS and with B2 blood involvement at the time brentuximab vedotin therapy was initiated. This single-center study was conducted at a major academic referral center. INTERVENTIONS: Intravenous brentuximab vedotin administration approximately every 3 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was the global response rate. Outcomes were assessed in the skin and lymph nodes per the 2011 European Organization for Research and Treatment of Cancer-International Society of Cutaneous Lymphoma response criteria and in the blood per the 2018 Prospective Cutaneous Lymphoma International Prognostic Index revised blood response criteria. RESULTS: The study included 13 patients (8 [62%] male; mean [SD] age, 68.2 [8.6] years). Of these 13 patients, 5 (38%) achieved a global response after a median of 6 cycles, including 1 complete response. Response rates by disease compartment were 38% in the skin, 63% in the blood, and 50% in the lymph nodes. Three of 11 patients (27%) with pruritus reported improvement. Skin CD30 positivity (>10%) was detected in 9 patients but was not associated with responses. Among responders, the median time to response was 6 weeks (range, 6-9 weeks), and the median duration of response was 5.5 months (range, 2.5-28.9 months). The median time to next treatment was 3.2 months (range, 1.5-36.7 months). Peripheral neuropathy occurred in 4 patients but resolved in 2 patients. Grade 2 adverse events were neuropathy (n = 2), constipation (n = 1), and hand-foot syndrome (n = 1). CONCLUSIONS AND RELEVANCE: In this case series, brentuximab vedotin use was associated with some efficacy in SS across multiple disease compartments and in the setting of refractory disease or low CD30 skin expression. Brentuximab vedotin may offer a manageable treatment schedule and low incidence of significant toxic effects.
引用
- Lewis DJ, Haun PL, Samimi SS, et al. Brentuximab Vedotin for Relapsed or Refractory Sézary Syndrome. JAMA Dermatol. 2021. PMID: 33377934. doi:10.1001/jamadermatol.2020.4901
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。